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Nrf2 is a master regulator of antioxidant cellular defence, and agents activating the Nrf2 pathway have been tested in various
diseases. However, unexpected side effects of cardiovascular nature reported for bardoxolone methyl in patients with type 2
diabetes mellitus and stage 4 chronic kidney disease (the BEACON trial) still have not been fully explained. Here, we aimed to
characterize the effects of bardoxolone methyl compared with other Nrf2 activators—dimethyl fumarate and L-
sulforaphane—on human microvascular endothelium. Endothelial toxicity, bioenergetics, mitochondrial membrane potential,
endothelin-1 (ET-1) release, endothelial permeability, Nrf2 expression, and ROS production were assessed in human
microvascular endothelial cells (HMEC-1) incubated for 3 and 24 hours with 100 nM–5 μM of either bardoxolone methyl,
dimethyl fumarate, or L-sulforaphane. Three-hour incubation with bardoxolone methyl (100 nM–5 μM), although not toxic to
endothelial cells, significantly affected endothelial bioenergetics by decreasing mitochondrial membrane potential
(concentrations ≥ 3μM), decreasing spare respiratory capacity (concentrations ≥ 1 μM), and increasing proton leak
(concentrations ≥ 500 nM), while dimethyl fumarate and L-sulforaphane did not exert such actions. Bardoxolone methyl at
concentrations ≥ 3 μM also decreased cellular viability and induced necrosis and apoptosis in the endothelium upon 24-hour
incubation. In turn, endothelin-1 decreased permeability in endothelial cells in picomolar range, while bardoxolone methyl
decreased ET-1 release and increased endothelial permeability even after short-term (3 hours) incubation. In conclusion, despite
that all three Nrf2 activators exerted some beneficial effects on the endothelium, as evidenced by a decrease in ROS production,
bardoxolone methyl, the most potent Nrf2 activator among the tested compounds, displayed a distinct endothelial profile of
activity comprising detrimental effects on mitochondria and cellular viability and suppression of endothelial ET-1 release
possibly interfering with ET-1–dependent local regulation of endothelial permeability.
1. Introduction
Nrf2—nuclear factor (erythroid 2-related factor) 2—is the
primary player in the inducible cell defence system that reg-
ulates expression of over 600 target genes including detoxifi-
cation, cytoprotective, and antioxidant enzymes; ABC
transporters; and other stress response enzymes and proteins
[1, 2]. The plethora of products encoded by these genes
includes antioxidant and cytoprotective genes (e.g. genes
related to glutathione synthesis, glutathione S-transferases,
thioredoxin, peroxiredoxins, hemoxygenase-1, and ferritin)
and many others, i.e., regulators of transcription, growth fac-
tors, and proteins responsible for xenobiotic metabolism and
clearance (reviewed in Baird and Dinkova-Kostova [3]).
Given the important role of Nrf2 in cellular defence, it
was not a surprise that Nrf2-/- mice were more susceptible
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to oxidative stress-induced diseases, including acute lung
injury, chronic obstructive pulmonary diseases, diabetic
nephropathy, heart failure, and cancer [4]. On the other
hand, Nrf2 pathway activation exerts a wide range of protec-
tive functions. There is a substantial interest in identifying
and developing Nrf2 activators that could be exploited ther-
apeutically in conditions related to oxidative stress and
inflammation, such as multiple sclerosis and complications
of diabetes (e.g., retinopathy and nephropathy), as well as
many other diseases including solid tumors, lymphomas,
and neurodegenerative diseases [1, 3–9].
L-sulforaphane, an isothiocyanate present in crucifer-
ous vegetables (broccoli), was one of the first studied acti-
vators of Nrf2. This compound was tested in a phase 2
clinical study in men with recurrent prostate cancer [10],
but the expected therapeutic effects were not achieved. How-
ever, in type 2 diabetic patients, L-sulforaphane-rich broccoli
sprout powder caused a significant improvement in serum
insulin concentration, glucose-to-insulin ratio, and insulin
resistance [11].
Another Nrf2 inducer, dimethyl fumarate, is a methyl
ester of fumaric acid—a metabolite of the citric acid cycle
in mitochondria. Dimethyl fumarate was tested in the treat-
ment of psoriasis where it decreased the number of T-cells
via the activation of apoptosis [12] and has been used in
the treatment of psoriasis for many years [13]. Importantly,
this compound has been shown to be efficacious in the treat-
ment of multiple sclerosis [14]. In a phase 3 clinical study in
relapsing-remitting multiple sclerosis patients, dimethyl
fumarate was shown to reduce the progression of disability
[15], and the compound was approved by FDA in 2013 for
the treatment of relapsing-remitting multiple sclerosis [16].
Some of the most promising Nrf2 inducers are the deriv-
atives of oleanolic acid [17]. A semisynthetic triterpenoid
derivative named bardoxolone methyl (also known as
CDDO-Me) is a potent Nrf2 inducer that stimulates Nrf2-
dependent cytoprotective responses in nanomolar concen-
trations [13, 17]. In multiple preclinical studies, bardoxolone
methyl was shown to reduce diabetic complications, cancer,
cardiovascular disease, neurodegenerative diseases, and
chronic obstructive pulmonary disorder [13, 17] and numer-
ous clinical trials were launched [1, 13, 17]. However, in
October 2012, a phase 3 BEACON trial was terminated. This
clinical study (Bardoxolone Methyl Evaluation in Patients
with Chronic Kidney Disease and Type 2 Diabetes Mellitus:
The occurrence of renal events (BEACON)) was a phase 3
randomized, double-blind, placebo-controlled trial designed
to determine whether bardoxolone methyl could reduce
End-Stage Renal Disease (ESRD) and cardiovascular events
[18]. The study was terminated due to safety concerns and
a significantly increased risk of heart failure requiring hospi-
talization, which also increased the composite cardiovascular
outcome (nonfatal myocardial infarction, nonfatal stroke,
hospitalization for heart failure, or death from cardiovascular
causes) in the bardoxolone methyl-treated group compared
to placebo [18]. Increased incidence of cardiovascular events
in bardoxolone methyl-treated patients in the BEACON trial
was attributed to the ability of bardoxolone methyl to mod-
ulate the endothelin pathway [18, 19]. An excess rate of
heart failure hospitalization among those assigned to the
bardoxolone-treated group was linked to fluid overload in
patients at risk [20] and seemed to recapitulate those
observed with endothelin receptor antagonists in patients
with advanced CKD [19, 21]. Furthermore, preclinical stud-
ies demonstrated the suppressive effects of bardoxolone
methyl on endothelin signalling in the kidneys by reducing
the expression of the ETA receptor protein, independently
of bardoxolone methyl-induced improvement of eGFR and
preservation of kidney function [19]. Given the fact that
ET-1 plays an important role in the regulation of sodium
and water homeostasis [22], it was claimed that bardoxolone
methyl may pharmacologically promote acute retention of
sodium and water through the modulation of the endothelin
pathway [21]. However, this hypothesis could not fully
explain the symptoms observed in patients suffering from
bardoxolone methyl-induced side effects [23], particularly
when post hoc analysis confirmed improved kidney function
and eGFR in bardoxolone methyl-treated patients [21]. Fur-
thermore, ET antagonists have different hemodynamic
effects from those induced by bardoxolone methyl, and gen-
erally, suppression of the endothelin pathway should rather
be protective than detrimental against an adverse cardiovas-
cular event [24–26]. Moreover, the manner in which bardox-
olone methyl modulates the endothelin pathway in other
tissues including the endothelium has yet to be examined,
and it is not known whether bardoxolone methyl displays
any detrimental effect on endothelial function—in particular
the endothelial barrier—that could possibly result in periph-
eral oedema. Endothelial function determines heart failure
progression not only by an NO-dependent action that is
known to have prognostic significance in heart failure
patients [27] but also by regulating the barrier function in
microcirculation. Indeed, changes in endothelial permeabil-
ity and vascular leakage could contribute to drug-induced
progression of heart failure and peripheral oedema, and such
detrimental mechanism in diabetic patients was reported for
rosiglitazone [28], a peroxisome proliferator-activated recep-
tor-γ (PPAR-γ) agonist, shown to significantly increase the
risk of heart failure [29]. Therefore, we aimed to test the
hypothesis that the detrimental effects of bardoxolone
methyl in the BEACON trial could be, at least partially,
explained by bardoxolone-induced effects on endothelial
function. For that purpose, in the present work we character-
ize the effects of bardoxolonemethyl on microvascular human
endothelium toxicity, mitochondrial function, endothelin-1
release, and endothelial permeability. The effects of bardoxo-
lone methyl were compared with those of two other well-
characterized Nrf2 activators used in clinical studies: dimethyl
fumarate and L-sulforaphane.
2. Methods
2.1. Cell Culture and Drug Treatment. Human dermal
microvascular endothelial cells, HMEC-1 (purchased from
ATCC, Cat. No. CRL3243™), were cultured in MCDB 131
Medium (Thermo Fisher Scientific) supplemented with
FBS (10%, Thermo Fisher Scientific), L-glutamine (2mM,
Thermo Fisher Scientific), hydrocortisone (0.05mg/ml,
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Sigma-Aldrich), Epidermal Growth Factor (5 ng/ml),
100U/ml penicillin, 10μg/ml streptomycin, and 250 ng/ml
amphotericin B (Sigma-Aldrich). HMEC-1 were cultured
under standard conditions (37°C, 5% CO2) and passaged
two times a week. In all experiments, cells between the sec-
ond and tenth passages were used only when they reached
full postplating confluency. Bardoxolone methyl (CDDO
methyl ester, Cayman Chemical), dimethyl fumarate
(Sigma-Aldrich), and L-sulforaphane (Sigma-Aldrich) ini-
tially diluted in DMSO were added to the culture medium
at final concentrations of 100nM, 300nM, 500 nM, 1μM,
3μM, and 5μM in triplicates, if not stated otherwise. Control
cells were treated with 0.05% DMSO added to the culture
medium. To check for acute toxicity, the cells were incubated
with tested agents for 3 hours. Standard toxicity assessment
time was set to 24 hours, according to the literature [30].
2.2. Assessment of Nrf2 Nuclear Expression. HMECs were
seeded at a density of 1,000,000 per well and grown in 6-
well plates until they reached full confluence, then cells were
incubated with bardoxolone methyl, dimethyl fumarate, and
L-sulforaphane for three hours. To measure Nrf2 expression
in the nucleus, a Nuclear Extract Kit (Active Motif) was used
to isolate the nuclear and cytoplasmic fractions. Nuclear and
cytoplasmic extracts (25 or 30μg protein/sample) were proc-
essed as follows: first, the membranes were scanned for total
protein content for further band normalization, and subse-
quently, they were incubated with primary rabbit polyclonal
Anti-Nrf2 Antibody (H-300) (sc-13032, Santa Cruz Biotech-
nology, lot No. GR197455-1) 1 : 1000 overnight and with goat
anti-rabbit secondary antibody (sc-2004, Santa Cruz Biotech-
nology, lot No. 12314) 1 : 2500 for 45 minutes. After chemilu-
minescent band detection, membranes were washed and
incubated with primary Anti-Lamin A/C Monoclonal Anti-
body (mab636, Thermo Fisher Scientific, lot No. QF215120)
1 : 1000 overnight and with anti-mouse secondary antibody
(sc-516102, Santa Cruz Biotechnology) 1 : 5000 for 1 hour.
Bands were again detected with the use of chemiluminescence,
measured and normalized to total protein content using Image
Lab Software (Bio-Rad).
2.3. Assessment of ROS Production. HMECs were cultured in
96-well plates (seeding density: 15,000 cells per well) and
treated with bardoxolone methyl, dimethyl fumarate, and
L-sulforaphane for 24 hours and incubated for 15 minutes
with the following fluorescent dyes: dihydroethidium DHE
(2μg/ml, Thermo Fisher Scientific) and Hoechst 33342
(0.5μl/ml, Thermo Fisher Scientific) at 37°C. After washing,
images were captured with an Olympus Scan^R automated
fluorescence microscope (Olympus Corporation) with the
use of 20x magnification in two channels: DAPI for nuclei
localization (Hoechst 33342, ex/em 346/460 nm) and Texas
Red for reactive oxygen species/reactive nitrogen species
(ROS/RNS) indication (DHE, ex/em 518/606 nm). Image
analysis was performed with the use of a Columbus Image
Data Storage and Analysis System (Perkin Elmer), and mean
fluorescence intensity was normalized to the number of
living cells.
2.4. Assessment of Endothelial Toxicity
2.4.1. MTS Tetrazolium Assay. HMECs were plated into 96-
well plates at a density of 15,000 per well in order to produce
confluency on the second postplating day. The cells were
incubated with bardoxolone methyl, dimethyl fumarate,
and L-sulforaphane for 3 and 24 hours. Cell viability was
determined with use of a Non-Radioactive Cell Proliferation
Assay (Promega) according to the manufacturer’s instruc-
tions. The absorbance was recorded at 490 nm using a Syn-
ergy4 plate reader (BioTek). Cells were then washed with
PBS and suspended in Mammalian Protein Extraction
Reagent (Thermo Fisher Scientific) containing phosphatase
(PhosSTOP, Roche) and protease (cOmplete, Roche) inhibi-
tors and frozen at -20°C. The next day, the samples were
thawed and total protein concentration was determined with
use of a colorimetric BCA Protein Assay Kit (Thermo Fisher
Scientific). Absorbance was recorded at 562nm. The results
of the MTS test were normalized to the protein concentration
of the sample and calculated as a percent of control cells.
2.4.2. Annexin V/Propidium Iodide Flow Cytometry Assay.
Flow cytometry was used to determine cellular apoptosis
and necrosis. HMECs were cultured in 24-well plates
(500,000 per well) and incubated for 3 and 24 hours with bar-
doxolone methyl, dimethyl fumarate, and L-sulforaphane
(single wells). After incubation, staining with Annexin V and
propidium iodide was performed with the use of a FITC
Annexin V Apoptosis Detection Kit (BD Biosciences) accord-
ing to the manual. The cells were analyzed with an LSR II flow
cytometer (Becton Dickinson).
2.4.3. Cell Counting. HMECs were cultured as described
above (Section 2.4.1) and treated with bardoxolone methyl
(100 nM-10μM), dimethyl fumarate (500 nM-1mM), and
L-sulforaphane (500 nM-100μM) for 24 hours. Afterwards,
the cells were washed with PBS 1x, fixed with 4% formalde-
hyde for 10min at RT, and incubated for 30 minutes at
37°C with the following fluorescent dyes: Hoechst 33258
(1μg/ml, Sigma-Aldrich) for nucleic acid staining and YO-
PRO-1 Iodide (1 : 1000, Thermo Fisher Scientific) for identi-
fication of apoptotic cells. Cell imaging was performed with a
Confocal Quantitative Image Cytometer CQ1 (Yokogawa
Electric Corporation) with the use of 10x magnification at
two wavelengths: 405/452 nm (blue) and 488/525 nm (green).
Image analysis was performed using a Columbus Image Data
Storage and Analysis System (Perkin Elmer).
2.5. Assessment of Mitochondrial Function. Cellular bioener-
getics were measured with use of the Seahorse XFe96 Ana-
lyzer (Agilent Technologies). Forty-eight hours prior to the
start of the experiment, cells were seeded at a density of
19,500 per well into 96-well XF cell culture plates, according
to the manufacturer’s protocol. Before the start of experi-
ments, cells were washed twice with 200μl of bicarbonate-
free low-buffered assay medium (containing 10mM glucose,
1mM pyruvate, and 2mM glutamine, pH = 7:4) and pre-
incubated for 1 hour with bardoxolone methyl, dimethyl
fumarate, and L-sulforaphane diluted in assay medium.
Changes in cellular respiration were assessed for 2 hours
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(total time of incubation with Nrf2 activators was three
hours). During the assay, sequential injections of 1μg/ml
oligomycin (an inhibitor of mitochondrial ATPase/ATP
synthetase), 0.7μM FCCP (trifluoromethoxy carbonylcya-
nide phenylhydrazone—a protonophore and uncoupler of
oxidative phosphorylation), and 1μM rotenone/antimycin
A (an inhibitor of mitochondrial electron transport at NAD-
H : ubiquinone oxidoreductase and an inhibitor of electron
transfer at complex III) were performed. Results regarding
the following parameters—basal respiration, proton leak,
maximal respiration, spare respiratory capacity, nonmito-
chondrial respiration, and ATP production—were obtained
with use of a test report generator provided by Agilent
Technologies.
Mitochondrial membrane potential was evaluated using
JC-1, which is a cationic dye that accumulates inside mito-
chondria. Depending on the value of the mitochondrial
membrane potential, it forms either red fluorescent aggre-
gates or green fluorescent monomers. A decrease in the red/-
green fluorescence intensity ratio indicates mitochondrial
depolarization. HMECs were plated into 96-well plates at a
density of 40,000 per well in order to produce confluency
on the first postplating day. After 3 hours of incubation with
bardoxolonemethyl, dimethyl fumarate, and L-sulforaphane,
cells were washed with PBS and incubated for 30 minutes at
37°C in the dark with 1μg/ml JC-1 (Thermo Fisher Scien-
tific). Shortly before JC-1 addition, 100μM FCCP was added
to the cells incubated with culture media to serve as a positive
control. Cell imaging was performed with a Confocal Quan-
titative Image Cytometer CQ1 (Yokogawa Electric Corpora-
tion) with the use of 20x magnification at two wavelengths:
561/617 nm (red) and 488/525 nm (green). Image analysis
was performed using a Columbus Image Data Storage and
Analysis System (Perkin Elmer).
2.6. Assessment of Endothelin-1 Release. HMECs were
plated into 96-well plates at a density of 15,000 per well and
treated with bardoxolone methyl, dimethyl fumarate, and
L-sulforaphane for 3 and 24 hours in duplicates. After the
assigned time, cell culture supernatants were collected, cen-
trifuged, and stored at -80°C. Endothelin-1 was quantified
with use of an ELISA Kit (R&D Systems). Total protein con-
centration was determined as described above and the results
were normalized.
2.7. Assessment of Endothelial Permeability. To measure
changes in endothelial permeability, we used the ECIS meth-
odology based on the measurement of cellular electric poten-
tial [31, 32]. HMEC-1 cells were seeded at a density of 30,000
per well into special 96-well plates containing golden elec-
trodes (Applied Biophysics). An ECIS array holder was
placed into the incubator, and cells were grown for approxi-
mately ten days until they reached full confluence confirmed
by ECIS readout (capacitance values: 0.5–1.0 nanoFarads).
One day prior to the start of the experiment, fully supple-
mented culture medium was changed to medium without
FBS. Endothelin-1 (100, 300, 500, and 1000 pM), selective
antagonists of ETA and ETB receptors BQ123 and BQ788
(1μM), bardoxolone methyl, dimethyl fumarate, and L-
sulforaphane (0.1–5μM) were added into the wells in qua-
druplicate and the impedance was measured throughout
24 hours. Control wells were treated with fresh culture
medium (no FBS), 0.05% DMSO, 5μM forskolin, and
10μM histamine.
2.8. Statistical Analysis. All parameters were expressed as
mean ± standard error of the mean (SEM). The data from
each experiment (repeated three times or more) were first
processed with the Shapiro-Wilk normality test, and all data
were normally distributed. Intergroup differences were
assessed by one-way analysis of variance (ANOVA), followed
by an adequate post hoc test (Duncan’s, Dunnett’s, or
Dunn’s), if appropriate.
3. Results
3.1. Effects of Bardoxolone Methyl, Dimethyl Fumarate, and
L-Sulforaphane on Nrf2 Expression in HMECs. To compare
the effects of bardoxolone methyl, dimethyl fumarate, and
L-sulforaphane on Nrf2 nuclear expression in HMECs, the
expression of Nrf2 in the nuclear fractions was assessed by
means of Western blots. As shown in Figure 1, bardoxolone
methyl at concentrations of 300nM and 3μM increased
Nrf2 expression in the nuclear fraction of HMECs by 17.5-
fold and 45-fold, respectively. L-sulforaphane appeared to
be less potent and dimethyl fumarate the least potent activa-
tor of Nrf2 because at a concentration of 3μM, these com-
pounds increased Nrf2 expression in the nuclear fraction of
HMECs by 9.3- and 3.1-fold, respectively (Figure 1(a)). In
the cytoplasmic fraction, a pronounced increase in the level
of Nrf2 was present only after treatment with 3μM of bar-
doxolone methyl (Figure 1(b)). Expression of Lamin A/C
was detected in the nuclear extracts, while it was absent in
the cellular fractions, confirming the nuclear fraction purity
(Figure 1(c)).
3.2. Effects of Bardoxolone Methyl, Dimethyl Fumarate, and L-
Sulforaphane on Reactive Oxygen Species (ROS) Generation in
HMECs. Incubation of HMECs with bardoxolone methyl for
twenty four hours at a concentration of 300nM resulted in a
significant decrease in ROS production measured by DHE
fluorescence, and this effect was even more pronounced in
the cells treated with 5μM bardoxolone methyl. Under sim-
ilar experimental conditions, dimethyl fumarate also pro-
duced a decrease in the DHE signal, but this effect was
clearly visible at the concentration of 5μM. Similarly, 5μM
of L-sulforaphane significantly lowered the DHE signal in
HMECs (Figure 2).
3.3. Endothelial Toxicity of Bardoxolone Methyl, Dimethyl
Fumarate, and L-Sulforaphane in HMECs. As shown in
Figure 3, bardoxolone methyl, dimethyl fumarate, and L-
sulforaphane after a 3-hour-long incubation did not cause
any significant changes in cell viability assessed by the MTS
reduction assay, with the exception of 1 and 5μM bardoxo-
lone methyl (Figures 3(a)–3(c)). However, after a 24-hour-
long treatment, bardoxolone methyl at a concentration range
of 100nM–1μM caused an increase in normalized MTS
reduction, while higher concentrations caused a substantial
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decrease in the parameter (IC50 = 3:23 μM) (Figure 3(d)). In
the same experimental conditions (24-hour-long drug treat-
ment), dimethyl fumarate given at micromolar concentra-
tions (1–50μM) caused an increase in MTS reduction
(Figure 3(e)). L-sulforaphane increased MTS reduction at
the concentration range of 500nM–10μM but not at the
highest concentrations used (30–50μM) (Figure 3(f)). To
confirm the obtained results, the effects of Nrf2 activators
on the cell count was tested using an extended concentration
range. Bardoxolone methyl did cause a significant decrease in
the number of living cells in the tested concentration range
after 24 hours of treatment (Figure 3(g)). Cell counting
revealed increasing dose-dependent toxicity of dimethyl
fumarate (IC50 = 95:52μM) at the concentration range of
500 nM–1mM (Figure 3(h)). Due to the compound solubil-
ity, the highest concentration of L-sulforaphane that could
be tested in order to not exceed a 0.05% concentration of
DMSO was 100μM, at the same time being the only toxic
concentration. The cells treated with 500nM–50μM did
not show neither an increase nor a decrease in cellular viabil-
ity (Figure 3(i)).
To characterize further effects of Nrf2 activators on cellu-
lar viability, apoptotic and necrotic cells were quantified by
flow cytometry with use of Annexin V and propidium iodide.
As shown in Table 1, HMECs treated for 24 hours with bar-
doxolone methyl (3 and 5μM) but not with dimethyl fuma-
rate or L-sulforaphane displayed a significantly diminished
subpopulation of live cells and increased subpopulations of



















































































Figure 1: Effects of Nrf2 activators on Nrf2 expression in endothelial cells. A representative Western blot analysis of Nrf2 expression in
nuclear (a, d) and cytoplasmic (b) fraction lysates obtained from HMEC-1 cells treated for 3 hours with 300 nM and 3μM of bardoxolone
methyl (Bm), dimethyl fumarate (Dmf), L-sulforaphane (L-s), culture medium alone, or with the addition of 0.05% DMSO. The
expression of Lamin A/C was also determined to define fraction purity and serve as loading control (c). The results (d) are presented
as a % of control ðDMSO0:05%Þ ± SEM, n = 3. The significance of the differences between the means was evaluated by one-way
analysis of variance (ANOVA) with Dunnett’s post hoc test; ∗p < 0:05 and ∗∗∗∗p < 0:0001 indicate significant difference vs. the control
group (DMSO 0.05%). The results were obtained in three independent experiments. In all panels, the first lane on the right contains a
protein molecular weight marker.
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necrotic and apoptotic+necrotic cells. There was no signifi-
cant difference between the control and experimental groups
in the composition of the cell population regarding live, apo-
ptotic, necrotic, and apoptotic+necrotic cells.
3.4. Effects of Bardoxolone Methyl, Dimethyl Fumarate, and L-
Sulforaphane onMitochondrial Respiration andMitochondrial
Membrane Potential in HMECs. To characterize the effects of
Nrf2 activators on endothelial bioenergetics, a mitochondrial
stress assay was performed in HMECs treated with bardoxo-
lone methyl, dimethyl fumarate, or L-sulforaphane for 3
hours. As shown in Figure 4, among all three Nrf2 activators,
bardoxolone methyl exerted the most pronounced actions: it
significantly increased proton leakage in a concentration-
dependent manner (0.5–5μM), decreased spare respiratory
capacity (3–5μM), and showed a tendency to decrease ATP
production that, however, did not reach statistical signifi-
cance (Figure 4(a)). Although low concentrations (100 and
300nM) of dimethyl fumarate increased basal respiration
and showed a tendency to increase spare respiratory capacity
and ATP production (Figure 4(b)), there were no other sig-
nificant effects of dimethyl fumarate on HMEC bioenerget-
ics. L-sulforaphane did not change any of the bioenergetic
parameters in a statistically significant fashion (Figure 4(c)).
Detrimental effects of bardoxolone methyl on mito-
chondria in endothelial cells were confirmed by the dem-
onstration that bardoxolone methyl (3 and 5μM) decreased
mitochondrial membrane potential as evidenced by a
decrease in the red/green fluorescence intensity of the JC-1
aggregate/monomer ratio, while dimethyl fumarate and L-
sulforaphane did not have any effect (Figure 5).
3.5. Effects of Bardoxolone Methyl, Dimethyl Fumarate, and
L-Sulforaphane on Endothelin-1 Release in HMEC Culture.
Bardoxolone methyl, but not the other Nrf2 activators,
caused a decrease in ET-1 concentration in the medium, even
upon a short-term, 3-hour-long incubation of HMECs with
the compound (Figure 6(a)). The effect of bardoxolone
methyl on ET-1 release was more pronounced (and concen-
tration dependent) when the incubation period was pro-
longed up to 24 hours (Figure 6(b)). Dimethyl fumarate at
almost all tested concentrations (0.1–5μM) slightly increased
ET-1 production in HMECs. L-sulforaphane in the lower
concentration range (0.1–0.3μM) slightly increased ET-1
production in HMECs, while a higher concentration of
L-sulforaphane (3–5μM) decreased ET-1 release in
HMECs. The inhibitory effect of L-sulforaphane on ET-1
release, however, was much less pronounced compared
with that of bardoxolone methyl (Figure 6(b)) and was
not observed after a 3-hour-long incubation (Figure 6(a)).
3.6. Effects of Bardoxolone Methyl, Dimethyl Fumarate, and
L-Sulforaphane on Endothelial Permeability in HMECs. As
shown in Figure 7, histamine (10μM) decreased and forsko-
lin (5μM) increased impedance, showing an increase and a
decrease in endothelial layer permeability, respectively
(Figure 7(a)), thus supporting the reliability of our experimen-
tal setup to study the endothelial barrier. To link the effects of
Nrf2 activators on endothelial permeability in HMECs with
ET-1 function, the effect of ET-1 given alone on endothelial
permeability was assessed. ET-1 caused a concentration-
dependent decrease in permeability (Figures 7(b) and 7(c)),
while ET-1 receptor antagonists BQ123 and BQ 788 increased
endothelial permeability (Figure 7(d)), as evidenced by
increased and decreased impedance, respectively.
Bardoxolone methyl (3 and 5μM), even after 3 hours of
incubation (that did not cause endothelial toxicity (Figure 3,
Table 1) but lowered ET-1 production (Figure 6)), significantly
decreased the impedance indicating an increase in the perme-
ability of the endothelial monolayer (Figure 8(a)), while
dimethyl fumarate did not disturb endothelial barrier func-
tion and L-sulforaphane at the highest concentrations had
only minor effects after 3 hours of incubation (Figures 8(b)
and 8(c)). After a 24-hour-long period of incubation, a
further increase in permeability of endothelial cells was
observed in the cells treated with micromolar concentra-
tions of bardoxolone methyl, an effect shared also by L-
sulforaphane (Figures 8(d) and 8(f)). In these experimental
conditions (24 hour incubation), dimethyl fumarate did
not affect endothelial permeability (Figure 8(e)).
4. Discussion
To the best of our knowledge, in the present work, we have
demonstrated for the first time that bardoxolone methyl
affects mitochondrial function, cellular viability, ET-1
release, and endothelial barrier function in human microvas-
cular endothelium, and those effects are not shared with
dimethyl fumarate and L-sulforaphane tested in the same
concentration range.
Clearly, the beneficial effect of Nrf2 on vascular endothe-
lial function has been repeatedly reported and evidenced, also
























































Figure 2: Effects of Nrf2 activators on reactive oxygen species
production in endothelial cells. HMEC-1 cells were incubated for
24 hours with bardoxolone methyl (Bm), dimethyl fumarate (Dmf),
and L-sulforaphane (L-s), (300 nM and 5 μM). Intensity values of
DHE fluorescence are expressed as relative fluorescence units ±
SEM, n = 3. The significance of the differences between the means
was evaluated by one-way analysis of variance (ANOVA) with
Dunnett’s post hoc test; ∗∗p < 0:01 and ∗∗∗∗p < 0:0001 indicate
significant difference vs. the control group (DMSO 0.05%). The
results were obtained in three independent experiments.
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effects include not only a decrease in vascular oxidative stress
but also a downregulation of endothelial proinflammatory
adhesion molecule expression [33] and restoration of endo-
thelial function in hypertension, atherosclerosis, diabetes, or
aging [7, 34, 35]. Here, by means of flow cytometry, we
detected direct endothelial toxicity for bardoxolone methyl
(at concentrations 3–5μM), but not for other Nrf2 activators,
which was not equivocally supported by the MTS assay in
any of the experimental groups, as the latter assay may show
divergent results if mitochondrial activity is altered. Indeed,
bardoxolone methyl seems to have a biphasic effect: it sus-
tains cellular metabolism at lower doses and becomes cyto-
toxic in higher concentrations; similarly, dimethyl fumarate
increased MTS readouts.
To better understand the mechanisms involved in bar-
doxolone methyl-induced endothelial toxicity, we analyzed
the effects of bardoxolone methyl compared with other
Nrf2 activators on cellular bioenergetics and mitochondrial
membrane potential. Although the main source of energy
in the endothelium is glycolysis [36], mitochondrial activity
and redox signalling plays an important role in maintaining
endothelial integrity [37]. We showed concentration-
dependent effects of bardoxolone methyl on mitochondrial









































































































































































































































































































































































































































































































Figure 3: Effects of Nrf2 activators on endothelial viability assessed by the MTS test and cell counting. HMEC-1 cells were incubated with
bardoxolone methyl, dimethyl fumarate, and L-sulforaphane (100 nM-50 μM) for 3 (a–c) and 24 (d–f) hours for the MTS test.
Concentrations ranging from 100 nM up to 1mM were applied in the cell counting test (g–i). Results are expressed as a % of control (cells
treated with 0.05% DMSO). Values are expressed as mean ± SEM, n = 4. The significance of the differences between the means was
evaluated by one-way analysis of variance (ANOVA) with Duncan’s (MTS) or Dunnett’s (cell counting) post hoc test if appropriate; ∗p <
0:05, ∗∗p < 0:01, and ∗∗∗∗p < 0:0001 indicate significant difference vs. the control group (DMSO 0.05%). The results were obtained in four
independent experiments.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































8 Oxidative Medicine and Cellular Longevity
and mitochondrial membrane potential. Interestingly, in
cells treated with bardoxolone methyl, an increase in proton
leak was observed even at the nontoxic concentration of
500nM. The uncoupling effect could be beneficial for the cell
[38–40]; however, the uncoupling effect of bardoxolone
methyl was severe and contributed to endothelial toxicity,
in particular in the presence of higher concentrations of bar-
doxolone methyl. Other Nrf2 activators—dimethyl fumarate
and L-sulforaphane—displayed neither endothelial toxicity




































































































































































































































































































































































































































































Figure 4: Effects of Nrf2 activators on mitochondrial function in endothelial cells. HMEC-1 cells were incubated for three hours with
bardoxolone methyl (a), dimethyl fumarate (b), and L-sulforaphane (c) (100 nM–5 μM). Values are expressed as mean oxygen
consumption rate (OCR, in pmol/min ± SEM, n = 5). The significance of the differences between the means was evaluated by one-way
analysis of variance (ANOVA) with Dunnett’s post hoc test if appropriate; ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗p < 0:001 indicate significant
difference vs. the control group (DMSO 0.05%). The results were obtained in five independent experiments.
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mitochondrial membrane potential, even at the highest con-
centrations used. The endothelial toxicity of bardoxolone
methyl was supposedly an Nrf-2-independent effect, since
increased Nrf2 activity may modulate mitochondrial func-
tion and has a protective, rather than detrimental effect on
mitochondrial integrity [41, 42]. On the other hand, the
effects of dimethyl fumarate on respiration could be linked
to the metabolism of dimethyl fumarate to fumarate, feeding
the citric acid cycle [16].
Many Nrf2-activating chemicals including bardoxolone
methyl are electrophilic, and their mechanisms of action are
based on the modification of cysteine residues in Keap1,
resulting in an impairment of Keap1 function, inhibition of
the ubiquitin E3 ligase activity of the Keap1-Cul3 complex,
and subsequently leading to Nrf2 activation. Electrophiles
are able to target distinct cysteine residues as well as lead to
rapid and selective depletion of mitochondrial glutathione
[43] implicating, at least partially, unspecific mechanisms of
action of these types of compounds [44]. Proteomic analysis
revealed that bardoxolone methyl interacts with 577 cellular
proteins [45]. It was suggested that the side effects of bardox-
olone methyl may be attributed to its highly reactive α-
cyano-α, β-unsaturated ketone (CUK) moiety in ring A,
which avidly reacts with other proteins besides Keap1. In
fact, modification of the CUK moiety in ring A results in a



































































































FCCP 100 𝜇M 
Bardoxolone
methyl 5 𝜇M
JC-1 aggregates JC-1 monomers
(b)
Figure 5: Effects of Nrf2 activators on mitochondrial membrane potential in endothelial cells. HMEC-1 cells were incubated for three hours
with FCCP (100 μM) or with bardoxolone methyl, dimethyl fumarate, and L-sulforaphane (100 nM–5 μM) (a). Values are expressed as a ratio
of red and green fluorescence intensity of JC-1 calculated as a % of control ± SEM, n = 3. The significance of the differences between the means
was evaluated by one-way analysis of variance (ANOVA) with Duncan’s post hoc test if appropriate; ∗p < 0:05 and ∗∗p < 0:01 indicate
significant difference vs. the control group (DMSO 0.05%). (b) Representative images of HMEC-1 cells treated with 0.05% DMSO (upper
panel), 5 μM of bardoxolone methyl (middle panel), and 100μM of FCCP (lower panel). Images were collected with the use of 20x
magnification at 561/617 nm (red fluorescence, JC-1 aggregates), 488/525 nm (green fluorescence, JC-1 monomers), and merged. The
results were obtained in three independent experiments.
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that the mitochondrial and cellular toxicity of bardoxolone
methyl reported here was due to an unspecific modification
of a thiol-containing mitochondrial protein, representing a
known mechanism of cellular toxicity described for other
agents [46]. Noteworthy, other mechanisms of bardoxolone
methyl-induced cellular toxicity reported for cancer cells
could also be involved in inducing endothelial toxicity by this
compound [47]. Interestingly, it was demonstrated that
dimethyl fumarate reduced cellular maximal respiratory
and reserve capacity and these effects were completely inhib-
ited by N-acetyl cysteine, again suggesting the involvement of
thiols [48]. These experiments were conducted in retinal epi-
thelial cells at a concentration of 10μM and a longer incuba-
tion period compared to our study. Also, L-sulforaphane was
shown to inhibit the proliferation of endothelial cells,
although the concentrations used were higher than those
investigated in our study [49]. These reports indicate that
unspecific detrimental effects of Nrf2 activators on mito-
chondrial bioenergetics and cellular function may be seen
not only with bardoxolone but also with other electrophilic
activators of Nrf2 in higher concentrations and in a tissue-
specific manner.
Increased risk of heart failure, hospitalization, or death
from heart failure in bardoxolone methyl-treated patients
in the BEACON trial was attributed to kidney-specific sup-
pression of the endothelin pathway resulting in sodium and
volume retention [19]. Given the fact that ET-1 directly
decreases microvascular permeability, the inhibition of the
ET-1-pathway in microvascular endothelium could increase
endothelial permeability. Indeed, in a set of ex vivo exper-
iments, ET-1 decreased permeability in rat mesenteric
microvessels [50, 51]. Furthermore, decreased microvascu-
lar permeability caused by ET-1 was suggested to be medi-
ated by the ETB receptor [50, 51]. These reports uncovered,
for the first time, an important role of ET-1 in the mainte-
nance and modulation of endothelial permeability. Recently,
Kansanen et al. [52] demonstrated that in human aortic
endothelial and human umbilical endothelial cells, nitro-
oleic acid, via an Nrf2-dependent pathway, leads to an
increased expression of the ETB receptor and a subsequent
decrease in extracellular ET-1 secreted by endothelial cells.
The authors postulated that this mechanism may limit the
vasoconstrictive effects of ET-1 and could prove therapeuti-
cally useful, for example, in pulmonary artery hypertension
[52]. Our results clearly indicate that ET-1 (in addition to
its well-known vasoconstrictive, mitogenic, and proinflam-
matory effects via ETA receptors, the NO- and PGI2-
releasing effect via the ETB receptor), quite surprisingly, is
also involved in maintaining the endothelial barrier function
in human microvascular endothelial cells. In fact, exogenous
ET-1 increased endothelial barrier function. Our experi-
ments are not conclusive regarding the type of ET-1 receptor
involved in the regulation of endothelial permeability by ET-
1, especially given a possible heterodimerization of receptor
A and B subunits [53]. However, the results presented in
the present work fully support the notion of ET-1 as a local
autocrine regulator of endothelial barrier function, as sug-
gested previously [50, 51, 54]. Even though downregulation
of ET-1 by laminar flow has vasoprotective effects and the
suppression of ET-1-dependent mechanisms by Nrf2 activa-
tors may be efficacious in the treatment of pulmonary arterial
hypertension (PAH) [33, 55], suppression of local ET-1 pro-
duction in the microcirculation may lead to increased endo-
thelial permeability.
In the present work, we demonstrate that bardoxolone
methyl suppressed ET-1 release from HMECs and increased
microvascular endothelial permeability. These effects were
seen even after 3 hours of incubation with bardoxolone
methyl, an experimental setting that was not associated with


















































































































































































Figure 6: Effects of Nrf2 activators on secretion of endothelin-1 from endothelium to culture media. HMEC-1 cells were incubated for 3 (a)
and 24 (b) hours with bardoxolone methyl, dimethyl fumarate, and L-sulforaphane (100 nM–5 μM). Values are expressed as mean ± SEM,
n = 3. The significance of the differences between the means was evaluated by one-way analysis of variance (ANOVA) with Dunnett’s post
hoc test if appropriate; ∗p < 0:0001 indicates significant difference vs. the control group (DMSO 0.05%). The results were obtained in three
independent experiments.
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lowered ET-1 production. Dimethyl fumarate did not dis-
turb endothelial barrier function after 3 hours of incubation,
and L-sulforaphane at the highest concentrations had only
minor effects that were also present after 24 hours of incuba-
tion, but again they were weaker as compared with bardox-
olone methyl.
Analysis of nuclear translocation of Nrf2 revealed that
in the tested concentration range of Nrf2 activators, bar-
doxolone methyl was the most potent inducer of the
Nrf2 pathway in HMECs, while L-sulforaphane was less
potent. These results are compatible with the weaker effects
of L-sulforaphane on ET-1 release and endothelial perme-
ability. Lack of significant effects of dimethyl fumarate could
be attributed to the weakest effects of this compound on Nrf2
among all three Nrf2 activators in the tested concentration
range. Indeed, L-sulforaphane was also shown by other
authors to be a more potent inducer of Nrf2 compared with
dimethyl fumarate [56]. It may also be that concomitant acti-
vation of other endothelial protective mechanisms by
increasing mitochondrial respiration (as evidenced in our
experiments) could play a role in a differential response of
cells to dimethyl fumarate vs. L-sulforaphane [57]. Obvi-
ously, in order to identify whether the effects of bardoxolone
methyl on ET-1 release and endothelial permeability are
indeed mediated by Nrf2, further experiments are needed,








































































































































































































Figure 7: Effects of endothelin-1 and endothelin-1 receptor antagonists on endothelial permeability. The measurement of impedance was
performed using an ECIS assay at a frequency of 16,000Hz in HMEC-1 cells: (a) incubated for one hour with medium, DMSO 0.05%,
histamine 10 μM, and forskolin 5 μM; (b and c) incubated for three hours with endothelin-1 (ET-1) (100 pM–1000 pM); (d) incubated for
three hours with 1 μM of BQ123 and/or BQ788. Values are expressed as mean normalized impedance ± SEM, n = 3. The significance of the
differences between the means was evaluated by one-way analysis of variance (ANOVA) with Dunnett’s post hoc test if appropriate; ∗p <
0:05, ∗∗p < 0:01, ∗∗∗p < 0:001, and ∗∗∗∗p < 0:0001 indicate significant difference vs. the control groups: medium (a) and DMSO 0.05%
(b, c, and d). The results were obtained in three independent experiments.
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Altogether, our results provide a novel insight into a pos-
sible detrimental influence of bardoxolone methyl on micro-
vascular endothelium that could have contributed to the side
effects of this compound reported in the BEACON study.
However, the concentration range used here was higher than





























































































































































































































































































Figure 8: Effects of Nrf2 activators on endothelial permeability. The measurement of impedance was performed using an ECIS assay at a
frequency of 16,000Hz in HMEC-1 cells incubated for 3 and 24 hours with bardoxolone methyl (a and d), dimethyl fumarate (b and e),
or L-sulforaphane (100 nM–5μM) (c and f). Values are expressed as mean normalized impedance ± SEM, n = 3. The significance of the
differences between the means was evaluated by one-way analysis of variance (ANOVA) with Duncan’s post hoc test if appropriate; ∗p <
0:05, ∗∗p < 0:01, and ∗∗∗∗p < 0:0001 indicate significant difference vs. the control group (DMSO 0.05%). The results were obtained in three
independent experiments.
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methyl [8]; thus, this conclusion needs further verification in
experimental studies, best to be performed in in vivo experi-
mental conditions.
In clinical trials comprising bardoxolone methyl,
dimethyl fumarate, or L-sulforaphane, Cmax plasma levels
found in patients were 24:7 ± 13:3 ng/ml (49 nM), 1.87mg/l
(13μM), and 36.7 ng/ml (210 nM), respectively [8, 10, 58].
These results suggest that for bardoxolone methyl and L-sul-
foraphane, nanomolar ranges of concentrations are close to
plasma concentration in patients, while it requires micromo-
lar concentrations for dimethyl fumarate. Still, we cannot
exclude that chronic treatment with bardoxolone methyl
in vivo, in particular in patients with preexisting alterations
of microvascular endothelial barrier function, e.g., due to dia-
betes, would result in the effects described in vitro using low
micromolar concentrations of this compound.
In conclusion, despite the limitations described above,
to the best of our knowledge, this study is the first to com-
prehensively evaluate the influence of three major Nrf2
activators on human microvascular endothelium to identify
an endothelium-oriented explanation for the side effects of
bardoxolone methyl reported in the BEACON clinical trial.
We have demonstrated that bardoxolone methyl displays a
distinct profile of activity in the endothelium, including
detrimental effects on mitochondria and cellular viability
and profound suppression of endothelial ET-1 release that
could possibly interfere with ET-1-dependent autocrine
regulation of endothelial permeability, safeguarding micro-
vascular function.
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